Less weight gain and hypoglycaemia with once‐daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients—The PREDICTIVE™ BMI clinical trial 1

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Diabetic Medicine

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-5491.2008.02483.x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

  2007cited by this paper
• Does insulin detemir have a role in reducing risk of insulin‐associated weight gain?

  2007cited by this paper
• Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index

  2007cited by this paper
• Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

  2007cited by this paper
• Insulin‐associated weight gain in diabetes – causes, effects and coping strategies

  2007cited by this paper
• Safety and efficacy of insulin detemir in clinical practice: 14‐week follow‐up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort

  2007cited by this paper
• Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

  2006cited by this paper
• Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes.

  2006cited by this paper
• Lower within‐subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

  2005cited by this paper
• Insulin detemir used in basal‐bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

  2005cited by this paper
• Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

  2005cited by this paper
• The 12-Month Efficacy and Safety of Insulin Detemir and NPH Insulin in Basal-Bolus Therapy for the Treatment of Type 1 Diabetes

  2004cited by this paper
• Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

  2004cited by this paper
• Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

  2004cited by this paper
• Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

  2004cited by this paper
• Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes

  2004cited by this paper
• A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.

  2003cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.

  2003cited by this paper
• Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes

  2003cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper

• Medical management of obesity.

  2023cites this paper
• Scientific advisory on nocturnal hypoglycemia in insulin-treated patients with diabetes: Recommendations from Indian experts.

  2022cites this paper
• Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline.

  2022cites this paper
• A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia.

  2022cites this paper
• Comparison of the Efficacy and Safety of Insulin Detemir Administered Once Daily According to Two Titration Algorithms (3-0-3 and 2-4-6-8) in Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus

  2019cites this paper
• Insulin Pharmacodynamics, Pharmacokinetics, and Insulin Regimens

  2019cites this paper
• Medications that cause weight gain and alternatives in Canada: a narrative review

  2018cites this paper
• Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis

  2016cites this paper
• The past, present, and future of basal insulins

  2016cites this paper
• Análisis de coste-efectividad de saxagliptina como tratamiento triple oral (con metformina y una sulfonilurea) en el manejo de la diabetes tipo 2 en España

  2016cites this paper
• The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

  2015cites this paper
• Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.

  2015cites this paper
• Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective

  2015cites this paper
• Combination therapy in type 2 diabetes mellitus

  2015cites this paper
• Effects of insulin therapy on weight gain and fat distribution in the HF/HS-STZ rat model of type 2 diabetes

  2015cites this paper
• Tools for Successful Weight Management in Primary Care

  2015cites this paper
• Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective.

  2014cites this paper
• Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A1chieve Sub-Analysis

  2013cites this paper
• A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes

  2013cites this paper
• The need for better insulin therapy

  2013cites this paper
• Safety and Efficacy of Modern Insulin Analogues

  2013cites this paper
• Sécurité et efficacité de l’insuline détémir en initiation chez les patients algériens diabétiques de type 2: Résultats de l’étude A1chieve

  2013cites this paper
• Addition of insulin aspart with basal insulin is associated with improved glycemic control in Indian patients with uncontrolled type 2 diabetes mellitus: the A1chieve observational study.

  2013cites this paper
• Review on the use of insulin in primary care.

  2013cites this paper
• Efficacy and safety of insulin treatment in type 2 diabetes using a new index called glucose safety control index

  2013influential citation
• Insulin detemir in the management of type 2 diabetes in non-Western countries: safety and effectiveness data from the A₁chieve observational study.

  2013influential citation
• Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.

  2013cites this paper
• Clinical Experience with Insulin Detemir: Results from the Bangladesh Cohort of Global A 1 chieve Study

  2013cites this paper
• The Comparison of 24-Hour Urinary Sodium, Albumin, and Protein Excretion in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus Using Insulin Detemir or Insulin Glargine

  2013cites this paper
• Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir

  2013cites this paper
• A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review

  2013cites this paper
• Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.

  2013cites this paper
• Metabolic Syndrome and Obesity : Targets and Therapy Insulin detemir for the treatment of obese patients with type 2 diabetes

  2012cites this paper
• Insulin detemir for the treatment of obese patients with type 2 diabetes

  2012cites this paper
• Insulin in the brain: there and back again.

  2012cites this paper
• Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes

  2012cites this paper
• Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta‐analysis

  2012cites this paper
• Brain meets body: the blood-brain barrier as an endocrine interface.

  2012cites this paper
• Insulin Detemir

  2012cites this paper
• The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus

  2012cites this paper
• Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden

  2012cites this paper
• Insulin Therapy in Home Health

  2012cites this paper
• İnsülin Analoglarinin Diyabetes Mellitus Tedavisindeki Rolü ve Faydalari Role and Benef its of Insulin Analogues in the Treatment of Diabetes Mellitus

  2012cites this paper
• Untersuchungen zur adipogenen Wirkung von Insulin Detemir auf 3T3-L1-Präadipozyten

  2012cites this paper
• Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.

  2011cites this paper
• Chronic insulin therapy reduces adipose tissue macrophage content in LDL-receptor-deficient mice

  2011cites this paper
• An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study.

  2011cites this paper
• The Starving Cell: Metabolic Syndrome as an Adaptive Process

  2011cites this paper
• Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.

  2011cites this paper
• COMPARISON OF MULTIPLE DAILY INSULIN INJECTION USING BASAL INSULIN DETEMIR AND CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN JAPANESE PATIENTS WITH TYPE 1 DIABETES

  2011cites this paper
• Management of diabetes across the course of disease: minimizing obesity-associated complications

  2011cites this paper
• Weight beneficial treatments for type 2 diabetes.

  2011cites this paper
• Management of patients with type 2 diabetes

  2011cites this paper
• Diabetes and weight management.

  2010cites this paper
• Are Analogue Insulins Superior to Human Insulin in Clinical Practice?

  2010cites this paper
• The addition of insulin to metformin and sulphonylureas: results of the 4‐T study

  2010cites this paper
• Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes

  2010cites this paper
• Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes

  2010cites this paper
• Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting

  2010cites this paper
• Differences between long-acting insulins for the treatment of type 2 diabetes

  2010cites this paper
• Insulin detemir is not transported across the blood-brain barrier.

  2010cites this paper
• Wczesne rozpoczęcie intensywnego leczenia insuliną u chorych na cukrzycę typu 2: dostępne dowody naukowe

  2009cites this paper
• Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy

  2009cites this paper
• Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?

  2009cites this paper
• Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial

  2009cites this paper
• Intensification with prandial insulin

  2009cites this paper
• The Intersection of Safety and Adherence: New Incretin‐Based Therapies in Patients with Type 2 Diabetes Mellitus

  2009cites this paper
• ea rly and Aggressive in itiation of in sulin t h erapy for t y pe 2 Diabetes: What i s the ev idence?

  2009cites this paper
• Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes

  2009cites this paper
• L'insulinothérapie chez les diabétiques de type deux

  2009cites this paper
• Lessons from DAWN: Implementing Effective Insulin Therapy

  2008cites this paper